 RTT News | FDA Further Restricts Use of Sanofi's Multaq Wall Street Journal Multaq had world-wide sales of $179 million in the first half of 2011. Early in 2011, the FDA told Sanofi to add to its label that "liver injury, including acute liver failure requiring transplant, has been reported in patients treated with Multaq." Heart drug doubles risk for heart failure FDA Alert : Multaq (Dronedarone) Increased Risk Of Death / Cardiovascular Problems Sanofi's Multaq Losing Rhythm? |
